Prospection
Deep Insights into Understanding Treatment Efficacy
Eric Chung, Co-founder and CEOProspection provides deep patient insights and enables evidence-based decisions to enhance health outcomes through its in-depth knowledge and selfserve analytics tool. It utilizes accurate real-world data to generate actionable patient-centric insights and find misdiagnosed or undertreated patients.
Prospection’s ready-to-use platform links analytics tools with real-world datasets (RWD) to offer real-world evidence (RWE) and insights for the US, Japan, the UK, Australia, and New Zealand. The platform also employs longitudinal-data-trained algorithms with deep, built-in condition expertise to deliver market-ready intelligence. Prospection has preloaded datasets of more than 400 million patients going through its analytical tools monthly.
This data trains algorithms to look through various patient sub-segments to recognize treatments that maximize outcomes.
“We focus on the pharmaceutical sector, especially in pulling rich insights out of our patient dataset to help pharmaceutical companies understand the patient journey and help them find the right candidates to put into their treatments,” says Eric Chung, cofounder and CEO of Prospection.
Prospection focuses on longitudinal analysis of a patient’s journey through time to find opportunities to optimize treatment through its proprietary platform that gathers actionable insights within a few seconds. Simultaneously, its longitudinal patient data (LPD) offering provides the most comprehensive picture of how well a treatment works by following a patient’s behavior over time.
LPD has historically been challenging to collect, and its usage in clinical research has been constrained. Prospection maps out entire patient journeys, integrates data points for doctor and clinic visits, diagnoses, comorbid conditions, and dispensed treatments to give the pharma industry access to knowledge previously thought inaccessible.
Leveraging its in-depth analytics, in-house clinical knowledge, and data library, Prospection does its homework before meeting with a client, deeply understanding what diseases the customer is interested in and their portfolio of drugs.
By processing and analyzing the data specific to a particular patient population of interest to the pharmaceutical brand, Prospection delivers insights that help identify cohorts that might benefit from a treatment review. Driving the creation of a specialized therapeutic environment, Prospection engages its customers, shows them insightful research data, and follows it up with personalized consulting.
On several occasions, Prospection has found RWE and insight into how some market-leading drugs were not the best treatment for specific patient subpopulations. It followed through by submitting the evidence to peerreviewed journals, helping similar patients access treatment reviews to consider alternatives.
Assuring a bright future with optimal results and patient care stability, Prospection aspires to continue offering services that add value to patient lives.
“We focus on the pharmaceutical sector, especially in pulling rich insights out of our patient dataset to help pharmaceutical companies understand the patient journey and help them find the right candidates to put into their treatments,” says Eric Chung, cofounder and CEO of Prospection.
Prospection focuses on longitudinal analysis of a patient’s journey through time to find opportunities to optimize treatment through its proprietary platform that gathers actionable insights within a few seconds. Simultaneously, its longitudinal patient data (LPD) offering provides the most comprehensive picture of how well a treatment works by following a patient’s behavior over time.
LPD has historically been challenging to collect, and its usage in clinical research has been constrained. Prospection maps out entire patient journeys, integrates data points for doctor and clinic visits, diagnoses, comorbid conditions, and dispensed treatments to give the pharma industry access to knowledge previously thought inaccessible.
We focus on the pharmaceutical sector, especially in pulling rich insights out of our patient dataset to help pharmaceutical companies understand the patient journey and help them find the right candidates to put into their treatments
By processing and analyzing the data specific to a particular patient population of interest to the pharmaceutical brand, Prospection delivers insights that help identify cohorts that might benefit from a treatment review. Driving the creation of a specialized therapeutic environment, Prospection engages its customers, shows them insightful research data, and follows it up with personalized consulting.
On several occasions, Prospection has found RWE and insight into how some market-leading drugs were not the best treatment for specific patient subpopulations. It followed through by submitting the evidence to peerreviewed journals, helping similar patients access treatment reviews to consider alternatives.
Assuring a bright future with optimal results and patient care stability, Prospection aspires to continue offering services that add value to patient lives.
| Share this Article: Tweet
|
Company
Prospection
Management
Eric Chung, Co-founder and CEO
Description
Enter Prospection, an organization aimed at improving health outcomes by enabling evidence-based decisions through a self-serve analytics tool that can pull the insights out. Prospection utilizes real world data to generate actionable patient-centric insights to find misdiagnosed or undertreated patients.
-1.jpg)
Prospection News
Prospection Appoints Technology-industry Veteran and Commercialization Leader Daniel West to Chief Executive Officer
SYDNEY - Prospection, announced software-as-a-service (SaaS) and go-to-market (GTM) seasoned executive, Daniel West, as Chief Executive Officer (CEO). Prospection also brings deep technology- and pharmaceutical-industry experience to its Board of Directors with the appointment of Craig Jones as its Chairperson and Bruce Goodwin as a Non-Executive Director. Prospection’s Co-founder, Eric Chung, will serve as Co-CEO, driving the crucial role of innovation and continued expansion into Japan.
Daniel leverages over twenty years of expertise in fostering business expansion and cultivating high-performing teams within prominent global technology firms. His career includes holding key leadership positions at renowned industry leaders like MYOB, Oracle, Salesforce, and Informatica. At Prospection, he plays a pivotal role in driving the ongoing business growth by spearheading global commercialization initiatives and pioneering artificial intelligence (AI) innovation. This innovation encompasses the utilization of advanced technologies such as large language models (LLMs) and various machine learning (ML) capabilities to enhance diagnostic, predictive, and prescriptive analytics.
“Daniel has a deep understanding of technology trends and the nuances of software commercialization that are invaluable to Prospection as we continue to enhance our global strategy and catapult our machine learning innovation,” said Eric. “With Daniel’s impressive background and Prospection’s decade-long reputation of successfully working with dozens of top-tier life sciences companies, we are well positioned to achieve growth and shepherd in patient-centric intelligence powered by AI.”
“I am personally inspired and professionally motivated by Prospection’s mission to help get the right patient on the right treatment at the right time,” said Daniel. “Today, we power patient-centric intelligence to help pharmaceutical commercial leaders elevate their impact on both patient care and market share. Tomorrow, we are a healthcare partner of choice to unlock the power of AI to understand what’s happening, diagnose why it’s happening, predict what might happen, and prescribe how to improve outcomes.”
Craig has recently joined Prospection, bringing with him a wealth of experience in facilitating the expansion of emerging enterprise technology companies to achieve their global aspirations. His track record includes playing a pivotal role in five successful acquisitions. Craig possesses a profound understanding of the worldwide Software as a Service (SaaS) and Artificial Intelligence (AI) arena. He has previously served as an Operating Advisor with the globally renowned technology investment firm Francisco Partners and has held senior executive positions at ABB Enterprise Software, Mincom, Oracle, and Descartes Systems Group.
“Prospection has built incredible, AI-forward technology supported by a team of healthcare analytics trailblazers,” said Craig. “I am excited to help elevate Prospection’s potential across the healthcare ecosystem.”
Bruce has joined Prospection, bringing with him over thirty years of extensive experience in the biopharmaceutical industry. His career includes executive roles within the Asia-Pacific region for Johnson & Johnson Innovative Medicine (formerly Janssen Pharmaceuticals). Bruce currently holds positions on the boards of five organizations within the healthcare sector, where he contributes his invaluable insights and expertise in global drug commercialization and a patient-centric approach.
“It is an honor to serve on Prospection’s Board of Directors. As a former customer of Prospection, I experienced firsthand the strong analytics innovation partnership and patient-centric intelligence software, which helped provide invaluable insight into patient care and market share,” said Bruce. “Over a number of years, our new product launches were world-class and Prospection was instrumental in achieving this.”